7 assistance programs for Prolia patients · 1 open today
One manufacturer copay card, for commercial insurance only — Amgen’s free-drug foundation does not cover Prolia.
Select the patient's insurance to see which programs may apply.
Current status · Award amounts · Eligibility · Direct application links · verified September 12, 2026
Prolia · Postmenopausal osteoporosis · Commercial insurance
Eligible patients may pay $0
Example · Prolia · 60 mg · 60 units · commercial plan · deductible met · 20% coinsurance · allowed amounts at the Medicare reference rate
| Without assistance | With Prolia Copay Card | |
|---|---|---|
| Drug responsibility | $361.21 | $0.00 |
| Administration (96372) | $3.07 | $3.07 |
| Patient owes | $364.28 | $3.07 |
Estimated patient savings: $361.21
CareCost calculates the drug and administration lines using the patient’s payer rate and benefits; this example uses the Medicare rate as a reference.
Maximum award $1,000
HealthWell Foundation fund for government-insured patients with Post Menopausal Osteoporosis (confirmed diagnosis).
Checked, and not available for this drug today
Free Amgen Safety Net Foundation for eligible patients
Change the diagnosis to see only the programs that apply to your patient.
Prolia shares this molecule with four biosimilars — Jubbonti, Stoboclo, Conexxence and Enoby. The Amgen programs above apply to Prolia only. If the payer mandates one of the other three products instead, use that manufacturer’s program below. (Each biosimilar also has an Xgeva-equivalent 120 mg oncology product — Wyost, Osenvelt, Bomyntra and Xtrenbo — not listed here, since this page covers the 60 mg osteoporosis line only.)
A biller who lands here after being told the payer mandates Jubbonti, Stoboclo or Conexxence instead of Prolia needs the program for that specific product, not the Amgen program above. None of the programs below cover the injection administration fee or the office visit — drug cost only.
Sandoz One Source Co-Pay Program & Sandoz Patient Assistance Program
Celltrion CARES Co-Pay Program & Celltrion CONNECT Patient Support Program
KabiCare Patient Support Program
Enoby (Q5167, Hikma) has no manufacturer copay card or patient assistance program — checked against Hikma.com, enobyinfo.com and launch materials on June 2, 2026. Hikma positions Enoby on a low list price instead of a support program, and CMS has never published an ASP payment limit for it in any quarter. A patient steered to Enoby by their payer has no manufacturer assistance to apply for.
These three programs are tracked separately from the Prolia programs above. None of them cover injection administration or office-visit fees, and none apply to patients on Medicare, Medicaid, TRICARE or VA insurance.
| Task | ✓ |
|---|---|
| Find programs for this insurance type | ✓ |
| See whether each program is open | ✓ |
| See maximum award | ✓ |
| Review key eligibility requirements | ✓ |
| Open the official application | ✓ |
| Calculate cost before assistance | ✓ |
| Apply the program benefit | ✓ |
| Calculate what the patient still owes | ✓ |
Commercial insurance — Eligible commercially insured patients may qualify for the Prolia Copay Card. Eligible patients may pay as little as $0 per dose, up to $4,500 per year, subject to current program terms. View current program ↑
Medicare — Manufacturer copay savings cannot be used when government insurance is paying for Prolia; the federal Anti-Kickback Statute is why, per HHS OIG guidance on copayment coupons. The Amgen Safety Net Foundation is not a fallback either: its covered-product list does not include Prolia. View current options ↑
Uninsured — Amgen’s own free-drug foundation does not cover this product. The Amgen Safety Net Foundation eligibility page names 16 Amgen medicines — Evenity, its other bone drug, among them — and neither Prolia nor Xgeva is on it (checked September 12, 2026). That leaves three real routes: a denosumab biosimilar at cash price, where Hikma publishes Enoby’s list price as $400 a syringe and $800 a year against Medicare’s $1,806.06 allowed amount for 60 mg of reference Prolia; a hospital or FQHC charity-care policy; or a diagnosis-matched foundation fund when one reopens. Check today’s status ↑
Why fund status matters — Manufacturer programs can change between: OPEN Accepting applications now · WAITLIST Not enrolling immediately · CLOSED Not accepting new applications. Every CareCost program card shows the status and the date it was verified.
Why the product name matters — Prolia and Xgeva bill the same HCPCS code (J0897) but are different products with different assistance programs. Confirm which product the patient is actually prescribed before applying.
Yes. The Prolia Copay Card is Amgen’s current manufacturer savings program. Eligible commercially insured patients may pay as little as $0, up to $4,500 per year. Apply on Prolia.com ↗ Calculate cost with the program →
No. Patients using Medicare or other government-funded insurance to pay for Prolia are not eligible for the manufacturer’s copay card. The Amgen Safety Net Foundation is not a fallback either — its eligibility page lists 16 Amgen products and Prolia is not one of them. Check current options ↑
Not from Amgen. The Amgen Safety Net Foundation’s product picker names 16 medicines — including Evenity, Amgen’s other bone drug — and neither Prolia nor Xgeva appears (checked September 12, 2026). What is left for an uninsured patient is a denosumab biosimilar at cash price (Hikma publishes Enoby’s list price as $400 a syringe, $800 a year), hospital or FQHC charity care, or a diagnosis-matched foundation fund if one reopens. Check today’s status ↑
Data current: programs verified Sep 12, 2026
Prolia Copay Card · Amgen Safety Net Foundation · Sandoz One Source Co-Pay Program · Sandoz Patient Assistance Program (Jubbonti) · Celltrion CARES Co-Pay Program · Celltrion CONNECT Patient Support Program (Stoboclo) · KabiCare Patient Support Program (Conexxence). Every program links directly to its official source or application page.
Last program check: .
Reviewed September 11, 2026 by Erin Rose, CareCost Estimate founder. Methodology →
CareCost